FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980253307> ?p ?o ?g. }

• W2980253307 endingPage "e0223658" @default.
• W2980253307 startingPage "e0223658" @default.
• W2980253307 abstract "Introduction Cervical cancer imposes a substantial health burden worldwide including in Australia and is caused by persistent infection with one of 13 sexually transmitted high-risk human papillomavirus (HPV) types. The objective of this study was to assess the cost-effectiveness of adding a nonavalent new Gardasil-9® (9vHPV) vaccine to the national immunisation schedule in Australia across three different delivery strategies. Materials and methods The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model was used to examine the cost-effectiveness of 9vHPV vaccine introduction to prevent HPV infection. Academic literature and anecdotal evidence were included on the demographic variables, cervical cancer incidence and mortality, treatment costs, and vaccine delivery costs. The incremental cost-effectiveness ratios (ICERs) were measured per disability-adjusted life years (DALYs) averted, using the heuristic cost-effectiveness threshold defined by the World Health Organisation (WHO). Analyses and data from international agencies were used in scenario analysis from the health system and societal perspectives. Results The 9vHPV vaccination was estimated to prevent 113 new cases of cervical cancer (discounted) during a 20-year period. From the health system and societal perspectives, the 9vHPV vaccination was very cost-effective in comparison with the status quo, with an ICER of A$47,008 and A$44,678 per DALY averted, respectively, using the heuristic cost-effectiveness threshold level. Considering delivery strategies, the ICERs per DALY averted were A$47,605, A$46,682, and A$46,738 for school, health facilities, and outreach-based vaccination programs from the health system perspective, wherein, from the societal perspective, the ICERs per DALY averted were A$46,378, A$43,729, A$43,930, respectively. All estimates of ICERs fell below the threshold level (A$73,267). Conclusions This cost-effectiveness evaluation suggests that the routine two-dose 9vHPV vaccination strategy of preadolescent girls against HPV is very cost-effective in Australia from both the health system and societal perspectives. If equally priced, the 9vHPV option is the most economically viable vaccine. Overall, this analysis seeks to contribute to an evidence-based recommendation about the new 9vHPV vaccination in the national immunisation program in Australia." @default.
• W2980253307 created "2019-10-18" @default.
• W2980253307 creator A5001758955 @default.
• W2980253307 creator A5020663415 @default.
• W2980253307 creator A5087199054 @default.
• W2980253307 date "2019-10-09" @default.
• W2980253307 modified "2023-10-16" @default.
• W2980253307 title "The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia" @default.
• W2980253307 cites W1549778880 @default.
• W2980253307 cites W1963612010 @default.
• W2980253307 cites W1964927845 @default.
• W2980253307 cites W1964963012 @default.
• W2980253307 cites W1983541835 @default.
• W2980253307 cites W2004935807 @default.
• W2980253307 cites W2020386919 @default.
• W2980253307 cites W2049579473 @default.
• W2980253307 cites W2110959817 @default.
• W2980253307 cites W2117042820 @default.
• W2980253307 cites W2119939498 @default.
• W2980253307 cites W2122365878 @default.
• W2980253307 cites W2133525827 @default.
• W2980253307 cites W2141985524 @default.
• W2980253307 cites W2143158562 @default.
• W2980253307 cites W2156900441 @default.
• W2980253307 cites W2157028861 @default.
• W2980253307 cites W2204668488 @default.
• W2980253307 cites W2276701634 @default.
• W2980253307 cites W2277177391 @default.
• W2980253307 cites W2335886932 @default.
• W2980253307 cites W2340030325 @default.
• W2980253307 cites W2409712475 @default.
• W2980253307 cites W2429993081 @default.
• W2980253307 cites W2470415918 @default.
• W2980253307 cites W2478092092 @default.
• W2980253307 cites W2559479498 @default.
• W2980253307 cites W2604091432 @default.
• W2980253307 cites W2607359198 @default.
• W2980253307 cites W2612177758 @default.
• W2980253307 cites W2734446500 @default.
• W2980253307 cites W2735894322 @default.
• W2980253307 cites W2738241331 @default.
• W2980253307 cites W2761318636 @default.
• W2980253307 cites W2807272918 @default.
• W2980253307 cites W2808318596 @default.
• W2980253307 cites W2812694051 @default.
• W2980253307 cites W2889646458 @default.
• W2980253307 cites W2896597103 @default.
• W2980253307 cites W2912326121 @default.
• W2980253307 doi "https://doi.org/10.1371/journal.pone.0223658" @default.
• W2980253307 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6785120" @default.
• W2980253307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31596899" @default.
• W2980253307 hasPublicationYear "2019" @default.
• W2980253307 type Work @default.
• W2980253307 sameAs 2980253307 @default.
• W2980253307 citedByCount "7" @default.
• W2980253307 countsByYear W29802533072021 @default.
• W2980253307 countsByYear W29802533072022 @default.
• W2980253307 countsByYear W29802533072023 @default.
• W2980253307 crossrefType "journal-article" @default.
• W2980253307 hasAuthorship W2980253307A5001758955 @default.
• W2980253307 hasAuthorship W2980253307A5020663415 @default.
• W2980253307 hasAuthorship W2980253307A5087199054 @default.
• W2980253307 hasBestOaLocation W29802533071 @default.
• W2980253307 hasConcept C112930515 @default.
• W2980253307 hasConcept C121608353 @default.
• W2980253307 hasConcept C126322002 @default.
• W2980253307 hasConcept C127454912 @default.
• W2980253307 hasConcept C142724271 @default.
• W2980253307 hasConcept C144024400 @default.
• W2980253307 hasConcept C149923435 @default.
• W2980253307 hasConcept C187212893 @default.
• W2980253307 hasConcept C18903297 @default.
• W2980253307 hasConcept C203014093 @default.
• W2980253307 hasConcept C22070199 @default.
• W2980253307 hasConcept C2776125615 @default.
• W2980253307 hasConcept C2778220009 @default.
• W2980253307 hasConcept C2778308922 @default.
• W2980253307 hasConcept C2778580637 @default.
• W2980253307 hasConcept C3019080777 @default.
• W2980253307 hasConcept C515549039 @default.
• W2980253307 hasConcept C64332521 @default.
• W2980253307 hasConcept C71924100 @default.
• W2980253307 hasConcept C86803240 @default.
• W2980253307 hasConcept C99454951 @default.
• W2980253307 hasConceptScore W2980253307C112930515 @default.
• W2980253307 hasConceptScore W2980253307C121608353 @default.
• W2980253307 hasConceptScore W2980253307C126322002 @default.
• W2980253307 hasConceptScore W2980253307C127454912 @default.
• W2980253307 hasConceptScore W2980253307C142724271 @default.
• W2980253307 hasConceptScore W2980253307C144024400 @default.
• W2980253307 hasConceptScore W2980253307C149923435 @default.
• W2980253307 hasConceptScore W2980253307C187212893 @default.
• W2980253307 hasConceptScore W2980253307C18903297 @default.
• W2980253307 hasConceptScore W2980253307C203014093 @default.
• W2980253307 hasConceptScore W2980253307C22070199 @default.
• W2980253307 hasConceptScore W2980253307C2776125615 @default.
• W2980253307 hasConceptScore W2980253307C2778220009 @default.
• W2980253307 hasConceptScore W2980253307C2778308922 @default.

• next